| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-02-08 | apalutamide (ARN-509, JNJ-56021927) | prostate cancer | 2 | Aragon Pharmaceuticals (USA - CA), now Johnson&Johnson (J&J) (USA - NJ) | Cancer - Oncology |
| 2013-02-05 | Xarelto® (rivaroxaban) and PRT4445 | Bayer (Germany) Janssen Pharmaceuticals (J&J - USA) Portola Pharmaceuticals (USA) | Cardiovascular diseases | ||
| 2013-02-04 | RhuDex® | primary biliary cirrhosis rheumatoid arthritis |
2 | Medigene (Germany) | Autoimmune diseases - Inflammatory diseases - Liver diseases - Rheumatic diseases |
| 2013-02-04 | anti-IgE vaccine | undisclosed |
1 | Pfizer (USA - NY) Cytos (Switzerland) | |
| 2013-02-01 | ATX-101 (proprietary formulation of synthetic sodium deoxycholate) | reduction of localized fat under the chin (submental fat) |
3 | Bayer (Germany) | Aesthetic area |
| 2013-01-31 | ACI-91 | Alzheimer's disease |
2 | AC Immune (Switzerland) | Neurodegenerative diseases |
| 2013-01-29 | pritelivir (AIC316) | genital herpes | 2 | Aicuris (Germany) | Infectious diseases |
| 2013-01-23 | urelumab (BMS-663513) and rituximab | B-cell non-Hodgkins lymphoma | 1b | BMS (USA - NY) | Cancer - Oncology |
| 2013-01-22 | antibody-drug conjugates (ADCs) | breast cancer non-small-cell lung cancer |
preclinical | Synthon (the Netherlands) | Cancer - Oncology |
| 2013-01-21 | AXL1717 (picropodophyllin) | anaplastic astrocytoma glioblastoma gliosarcoma anaplastic oligodendroglioma anaplastic oligoastrocytoma anaplastic ependymoma |
1-2 | Axelar (Sweden) | Cancer - Oncology |
| 2013-01-18 | AZD0424 | various solid tumors |
1 | AstraZeneca (UK) Cancer Research UK’s Drug Development Office (UK) | Cancer - Oncology |
| 2013-01-17 | anti VEGF DARPin MP0112 | wet age-related macular degeneration (wet AMD) diabetic macular edema (DME) |
1-2a | Molecular Partners (Switzerland) | Ophtalmological diseases |
| 2013-01-17 | IFN-free investigational polymodal regimen combining faldaprevir (BI 201335), BI 207127 plus ribavirin. | hepatitis C |
3 | Boehringer Ingelheim (Germany) | Infectious diseases |
| 2013-01-16 | AT13148 | several undisclosed cancer types | 1 | Astex Pharmaceuticals (USA) Cancer Research UK (UK) Cancer Research Technology (CRT) (UK) | Cancer - Oncology |
| 2013-01-10 | Renevia™stem cell delivery platform | restoration of subcutaneous tissue lost as a result of injury, oncologic resection, or congenital defects | BioTime (USA) | Regenerative medicine | |
| 2013-01-09 | NuQ® tests (Nucleosomics® diagnostic products) | breast cancer colorectal cancer |
VolitionRx (Singapore) Wales Cancer Bank (UK) | Cancer - Oncology | |
| 2013-01-08 | velusetrag (TD-5108) | diabetic or idiopathic gastroparesis |
2 | Theravance (USA) Alfa Wassermann (Italy) | Gastroenterology - Digestive diseases |
| 2013-01-07 | ponatinib (Iclusig®) | chronic myeloid leukemia |
3 | Ariad Pharmaceuticals (USA - MA) Newcastle University (UK) | Cancer - Oncology |
| 2013-01-07 | empagliflozin (BI 10773) | type 2 diabetes | 3 | Boehringer Ingelheim (Germany) - Eli Lilly (USA) | Metabolic diseases |
| 2013-01-03 | ALKS 3831 (combination of a proprietary drug molecule, ALKS 33/samidorphan and olanzapine -Zyprexa®) | schizophrenia | 1 | Alkermes (Ireland) | Mental diseases |
